Hepatocellular adenoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 20: | Line 20: | ||
* The [[adenoma]] is < 5 cm in diameter | * The [[adenoma]] is < 5 cm in diameter | ||
* It has [[Regression|regressed]] to < 5 cm after discontinuation of [[Oral contraceptive|oral contraceptive medications]] | * It has [[Regression|regressed]] to < 5 cm after discontinuation of [[Oral contraceptive|oral contraceptive medications]] | ||
==References== | ==References== | ||
Latest revision as of 13:10, 23 August 2019
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma secondary prevention |
|
Risk calculators and risk factors for Hepatocellular adenoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
An annual follow-up with MRI or ultrasound may be scheduled for female patients until menopause.
Secondary Prevention
An annual follow-up with MRI or ultrasound may be scheduled for female patients until menopause, when:[1]
- The adenoma is < 5 cm in diameter
- It has regressed to < 5 cm after discontinuation of oral contraceptive medications
References
- ↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter
|month=ignored (help)